

Neuroblastoma Histopathology Reporting Guide



Family/Last name	Date of birth DD - MM - YYYY
Given name(s)	
Patient identifiers	Date of request Accession/Laboratory number
Elements in black text are CORE. Elements in grey text are indicates multi-select values indicates single select	SCOPE OF THIS DATASET
CLINICAL INFORMATION ☐ Information not provided Age ☐ Information not provided ☐ <18 months ☐ ≥18 months and <5 years ☐ ≥5 years Preoperative treatment ☐ Information not provided ☐ No known preoperative therapy ☐ Preoperative therapy given, specify Previous biopsy ☐ Information not provided ☐ No previous biopsy ☐ Previous biopsy	TUMOUR SITE Not specified Adrenal/periadrenal Retroperitoneal, nonadrenal Thoracic paraspinal Cervical region Other, specify Primary site Metastatic site
Core needle biopsy Excisional/open biopsy Other, specify	TUMOUR DIMENSIONS (Applicable to primary resections only) Greatest dimension mm
Known cancer predisposition syndrome, specify	Additional dimensions mm x mm Cannot be assessed, specify
Other clinical information, specify	BLOCK IDENTIFICATION KEY (List overleaf or separately with an indication of the nature and origin of all tissue blocks)
OPERATIVE PROCEDURE Not specified Resection Excisional/open biopsy Core needle biopsy Fine needle aspiration (FNA) Bone marrow aspirate/core biopsy Other, specify	HISTOLOGICAL TUMOUR TYPE (select all that apply) (Value list based on the World Health Organization Classification of Paediatric Tumours (2023)) (Not applicable for tumours post chemo/radiotherapy) Ganglioneuroma Ganglioneuroblastoma, intermixed Neuroblastoma Ganglioneuroblastoma, nodular Other, specify

(Applicable to neuroblastoma or nodules of ganglioneuroblastoma, nodular, that have not had chemo/radiotherapy) Undifferentiated Poorly differentiated Differentiating Cannot be determined, specify	ANCILLARY STUDIES Not performed Performed MYCN status Not applicable Cannot be determined Pending Not amplified Amplified Gain DNA content
MITOTIC-KARYORRHECTIC INDEX (MKI) (Applicable to neuroblastoma and ganglioneuroblastoma, nodular tumour tissue that have not had chemo/radiotherapy) Low (<100 per 5,000 cells; <2%) Intermediate (100-200 per 5,000 cells; 2-4%) High (>200 per 5,000 cells; >4%) Cannot be determined, specify	DNA ploidy Record method Results pending DNA index 1.0 (diploid) DNA index >1.0 (hyperdiploid) DNA index, specify value
PROGNOSTIC CLASSIFICATION	AND/OR CNV Record method
(Based on the International Neuroblastoma Pathology Committee classification) (Not applicable for tumours post chemo/radiotherapy) Favourable Favourable, based on review of limited material Unfavourable Cannot be determined, specify	Record result Results pending
TREATMENT EFFECT	Immunohistochemistry, specify antibodies and results
Not identifiedPresent	
Cannot be assessed No nodes submitted or found Number of lymph nodes examined Not involved Involved	Other (e.g., ALK), record test(s), methodology and results
Number of involved lymph nodes Number cannot be determined Location of involved lymph nodes, specify	Representative blocks for ancillary studies, specify those blocks best representing tumour and/or normal tissue for further study

ONAL MATERIAL FOR E	BIOLOGICAL/GENETIC
al available	
	d
Histologically assessed	
Viable tumour prese	nt
○ No ○ Yes	l
	viable tumour present
%	neuroblastic cells
%	Schwann cells
%	other cells (e.g., lymphoid cells, fibroblasts)
applicable identified sent (select all that apply) Liver Skin Bone marrow Percentage of haemopo by tumour Cannot be determ ≤5% >5%, specify Bone, specify site(s)	ietic bone marrow replaced nined %
Soft tissue, specify site((s)
Other, specify site(s)	
	Not histological assesse Histologically assessed Viable tumour preservition No Yes GICALLY CONFIRMED applicable identified sent (select all that apply) Liver Skin Bone marrow Percentage of haemopo by tumour Cannot be determ S5% >5%, specify Bone, specify site(s)